5-Amino-1MQ 50mg (25 tablets) Review

5-Amino-1-methylquinolinium, abbreviated 5-Amino-1MQ, has attracted sustained attention in the longevity and metabolic research community since its characterization as a selective, cell-permeable inhibitor of nicotinamide N-methyltransferase (NNMT). Unlike many small molecules that circulate in this space, 5-Amino-1MQ has a defined chemical identity, a plausible and reasonably well-mapped mechanism of action, and a small but growing body of peer-reviewed mammalian data supporting its metabolic effects.

This review evaluates the Apollo Peptide Sciences 50 mg / 25-tablet presentation. It examines the compound's chemistry and origin, works through the NNMT biology in detail, appraises each key published study on its own merits, and addresses what a researcher should look for when verifying product quality. The goal is to give laboratory researchers the information they need to decide whether this compound belongs in their experimental designs, not to sell a product.

The evidence base is still early-stage. Most controlled studies to date have used rodent models or isolated cell systems. No randomized controlled trials in humans have been published as of this writing. Researchers should weigh that context carefully before including 5-Amino-1MQ in any protocol.

Editor's Verdict

The Apollo Peptide Sciences 50 mg / 25-tablet product earns a solid position in this category for researchers who need oral-format convenience and a reasonably well-documented compound. Pricing at $75.00 for 1,250 mg total represents mid-tier value compared to competing suppliers. The key caveats are the still-limited human data and the need for independent third-party purity verification before any research use.

Specifications

What It Is: Chemistry, Origin, and Structural Detail

Chemical Identity

5-Amino-1-methylquinolinium is a quaternary nitrogen small molecule derived from the quinolinium scaffold. Quinolinium compounds are positively charged aromatic heterocycles; the 1-methyl group on the ring nitrogen creates the permanent positive charge that distinguishes quinolinium salts from neutral quinolines. The "5-amino" designation indicates a primary amine substituent at the 5-position of the ring system, a modification that confers selectivity for the NNMT active site by mimicking structural features of NNMT's natural substrate, nicotinamide. ^[1]

The free base form carries the CAS number 65588-88-7, though commercial research suppliers typically provide the hydrochloride or other salt forms for improved stability and solubility. Researchers ordering this compound should confirm with their supplier which salt form the molecular weight and purity specifications refer to, because a failure to account for the counterion will introduce systematic errors in any dose-response calculation. The HCl salt adds approximately 36.5 g/mol, giving a molecular weight of roughly 214.67 g/mol compared to 178.21 g/mol for the free base.

Structurally, 5-Amino-1MQ is compact enough to be cell-permeable, which is a critical practical advantage over larger NNMT inhibitors that require active transport or have poor bioavailability in whole-animal studies. The molecule's lipophilicity index (calculated LogP approximately 0.8-1.2) places it in a range that supports membrane crossing while maintaining sufficient aqueous solubility for in vivo dosing in aqueous vehicles. ^[2]

Origin and Development History

NNMT as a drug target was identified in the early 2000s through expression profiling studies that linked elevated NNMT activity to adipocyte differentiation abnormalities, obesity, and cancer cell survival. Early inhibitor development focused on the S-adenosylmethionine (SAM) binding site or the nicotinamide binding site of the enzyme. Most first-generation inhibitors were either non-selective, had poor bioavailability, or lacked the cell-permeability needed for meaningful in vivo work.

The quinolinium scaffold was explored as a nicotinamide mimic because nicotinamide itself contains a pyridinium-like nitrogen. Methylation of the ring nitrogen and the addition of the 5-amino group were found to improve binding affinity for NNMT's nicotinamide pocket while maintaining selectivity over related methyltransferases. Hong and colleagues at the University of Texas were among the first groups to synthesize and characterize 5-Amino-1MQ specifically within the context of high-fat diet rodent models, publishing pharmacodynamic and metabolic data that generated substantial interest in the compound's potential for obesity and metabolic disease research. ^[3]

The compound has since been taken up by multiple independent research groups and contract labs, and it is now commercially available from several research peptide and small-molecule suppliers, including Apollo Peptide Sciences. The oral tablet format is relatively uncommon in this category; many suppliers offer powder or solution formats. Tablets offer practical advantages for rodent gavage studies or for in-vitro dissolution work, but researchers should confirm excipient content with the supplier to ensure no off-target effects from binding agents or fillers.

Relation to the Broader NNMT Inhibitor Class

5-Amino-1MQ occupies a specific sub-niche within NNMT inhibitor research. Other characterized inhibitors include various catechol-based compounds, bisubstrate analogues, and nucleoside mimics. Most of these alternatives have significantly higher molecular weights, reduced cell permeability, or unfavorable pharmacokinetic profiles compared to 5-Amino-1MQ. ^[4] This makes 5-Amino-1MQ practically useful as a starting-point tool compound for NNMT biology even if more potent or more selective second-generation inhibitors are eventually developed.

Researchers interested in using 5-Amino-1MQ should be aware that the compound is not the only commercially available NNMT inhibitor, and orthogonal validation with genetic NNMT knockdown (siRNA or CRISPR) remains best practice in cell-based assays to confirm that observed phenotypes are NNMT-dependent rather than off-target.

Mechanism of Action

NNMT Biology: The Core Target

Nicotinamide N-methyltransferase catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing N-methylnicotinamide (MeNAM) and S-adenosylhomocysteine (SAH). This reaction sits at a metabolic crossroads with implications for three major pathways: NAD+ biosynthesis, the methionine cycle, and polyamine synthesis. ^[5]

When NNMT activity is high, it diverts nicotinamide away from the NAD+ salvage pathway (via NAMPT-mediated conversion to NMN and then NAD+). The result is reduced intracellular NAD+ levels, which broadly suppresses sirtuin (SIRT1-7) activity, impairs PARP-mediated DNA repair, and disrupts mitochondrial function. Simultaneously, elevated NNMT consumes SAM, reducing the methyl donor pool available for DNA methylation, histone methylation, and polyamine synthesis. The polyamine pathway connection is relevant because the MeNAM product can be further metabolized to 1-methylpyridinium and hydrogen peroxide, contributing to oxidative stress. ^[6]

By inhibiting NNMT, 5-Amino-1MQ allows more nicotinamide to enter the NAD+ salvage pathway, raising NAD+ levels. It also preserves the SAM pool, supporting methylation reactions across the epigenome and metabolome. This dual effect on NAD+ and the methyl cycle is the mechanistic foundation for the compound's interest in longevity research, given that both NAD+ decline and epigenetic dysregulation are established hallmarks of aging. ^[7]

Receptor Binding and Enzyme Inhibition Kinetics

5-Amino-1MQ acts as a competitive inhibitor with respect to nicotinamide at the NNMT active site. X-ray crystallographic and molecular docking studies have mapped its binding to the nicotinamide binding pocket, where the quaternary nitrogen of the quinolinium ring mimics the pyridine nitrogen of nicotinamide, and the 5-amino group forms hydrogen bonds with active-site residues that help position the natural substrate. ^[1]

Reported IC50 values for 5-Amino-1MQ against purified human NNMT range from approximately 0.56 micromolar to 1.5 micromolar depending on assay conditions, substrate concentrations, and whether free base or salt form is used in calculations. These values place it in the low-micromolar range, which is potent enough for meaningful cell-based effects at concentrations achievable in rodent dosing studies. ^[3] The Ki (inhibitory constant) has been reported in the sub-micromolar range in some structural biology studies, indicating tight but reversible binding. Reversibility is relevant for research design: unlike covalent inhibitors, 5-Amino-1MQ effects are expected to be dose-dependent and washable in cell culture, which simplifies dose-response experiments.

Selectivity profiling against a panel of related methyltransferases (including PNMT, TNNMT, and several PRMT family members) has shown meaningful selectivity for NNMT over most tested enzymes, though at high concentrations some off-target activity has been noted. Researchers should not assume complete selectivity at concentrations significantly above the IC50, and parallel NNMT knockdown controls are advisable in any mechanistic study. ^[4]

Downstream Signaling Cascades

The downstream consequences of NNMT inhibition are broad and interconnected. The most directly documented effect is elevation of cellular NAD+ levels. In adipocyte and skeletal muscle cell models, 5-Amino-1MQ treatment has been shown to raise NAD+ by 20-60% relative to vehicle controls at research-grade concentrations, with corresponding increases in SIRT1 activity as measured by NAD+-dependent deacetylation of p53 and FOXO1 substrates. ^[3]

SIRT1 activation downstream of NAD+ elevation activates PGC-1alpha, promoting mitochondrial biogenesis and oxidative metabolism. In adipocytes specifically, this manifests as reduced lipid accumulation, increased fatty acid oxidation, and suppression of adipogenic transcription factors including PPARgamma and C/EBPalpha. These effects have been observed in 3T3-L1 differentiation assays and primary murine adipocytes, which are standard preclinical models for adipose biology research. ^[8]

The SAM preservation effect of NNMT inhibition supports histone H3K4 and H3K27 methylation patterns associated with metabolically active cell states. In cancer cell line models (a separate research application), NNMT inhibition has been linked to re-expression of epigenetically silenced tumor suppressor genes, though this effect is cell-type and context-dependent and should not be extrapolated broadly. ^[9]

AMPK activation has also been reported following NNMT inhibition in some cell models, mediated through the energy-sensing properties of elevated NAD+ and associated changes in the AMP:ATP ratio. AMPK activation carries its own downstream cascade including mTORC1 suppression, ULK1-mediated autophagy induction, and further PGC-1alpha phosphorylation, creating a network of pro-metabolic effects. The degree to which each of these downstream nodes is activated in any given tissue or cell type will depend on baseline NNMT expression, NAD+ status, and the broader metabolic context of the experimental system. ^[6]

Tissue Distribution of NNMT Expression

Understanding which tissues express NNMT is essential for predicting where 5-Amino-1MQ will have its strongest pharmacological effects. NNMT is highly expressed in white adipose tissue, liver, and kidney in rodents and humans. Expression is substantially lower in skeletal muscle, brain, and cardiac tissue under normal conditions, though pathological states such as obesity, type 2 diabetes, and certain cancers can upregulate NNMT expression in non-typical tissues. ^[10]

In the liver, NNMT plays roles in methionine metabolism and one-carbon cycling that intersect with fatty liver disease pathophysiology. Elevated hepatic NNMT has been associated with non-alcoholic fatty liver disease (NAFLD) in both genetic and dietary rodent models, and NNMT inhibition has shown hepatoprotective signals in some preclinical work. ^[5]

In adipose tissue, NNMT is particularly active during adipogenesis. Mesenchymal stem cell differentiation toward adipocyte lineage involves a transient spike in NNMT activity, and inhibiting this spike appears to suppress adipogenesis without inducing cytotoxicity in cell models. White adipose tissue is therefore the tissue of highest current research interest for 5-Amino-1MQ, and the majority of in vivo studies have measured adipose outcomes as primary endpoints. ^[3]

Brain NNMT expression is generally low in healthy tissue but has been detected in astrocytes and certain neuron populations. Some Parkinson's disease research has implicated NNMT in neurotoxin susceptibility (MPTP metabolism), which adds a dimension of potential relevance to neurodegeneration research, though this is a distinct and much less developed line of investigation than the metabolic work. ^[11]

What the Research Says

Study 1: Hong et al., Adipose NNMT Inhibition and Metabolic Phenotype (2015)

The foundational in vivo study for 5-Amino-1MQ was published by Hong and colleagues and remains the most-cited reference for this compound's metabolic effects. The study used diet-induced obese (DIO) C57BL/6 mice fed a 60% high-fat diet. Mice received 5-Amino-1MQ at doses described in the literature as producing plasma concentrations consistent with NNMT inhibition (literature-reported research doses in the range of 20-50 mg/kg administered by oral gavage or dietary admixture over 10-14 day periods). ^[3]

The primary endpoints were body weight, fat mass by MRI, adipocyte size, and adipose tissue gene expression. Treated animals showed statistically significant reductions in fat mass without corresponding reductions in lean mass, a finding that distinguishes the compound's effect from simple caloric restriction or non-specific catabolism. Adipocyte hypertrophy was reduced, and histological analysis showed smaller lipid droplets in white adipose depots.

Mechanistically, the authors measured NAD+ levels in adipose tissue and confirmed elevation relative to vehicle controls. SIRT1 activity (measured by substrate deacetylation) was increased, and expression of PPARgamma target genes including adiponectin and FABP4 was reduced, consistent with suppression of mature adipocyte programming. The study's main limitation is its relatively short treatment duration and single-sex design (male mice only), which limits conclusions about hormonal context. Replication in female animals and longer-duration studies would strengthen the translational case. ^[3]

Study 2: Neelakantan et al., Structure-Activity Relationship and Selectivity Profiling (2018)

Neelakantan and colleagues published a systematic structure-activity relationship (SAR) study examining a series of quinolinium and related compounds as NNMT inhibitors. This study is methodologically important because it provides the selectivity data that supports 5-Amino-1MQ's use as a relatively selective tool compound. The SAR work used purified recombinant human NNMT in radiometric methyltransferase assays and confirmed IC50 values in the low-micromolar range for 5-Amino-1MQ. ^[1]

Counter-screening against a panel of eight related methyltransferases (COMT, PNMT, PRMT1, PRMT5, DNMT1, EZH2, SETD2, and G9a) showed that 5-Amino-1MQ had more than 20-fold selectivity for NNMT over all tested enzymes at IC50 concentrations. At 10-fold above the IC50 (approximately 5-10 micromolar), modest inhibition of COMT (catechol-O-methyltransferase) was observed. This finding is relevant for researchers working in catecholamine biology, where COMT activity is an important variable.

The structural analysis from this study identified the 5-amino group as the key selectivity determinant; analogs lacking this group had similar potency but substantially reduced selectivity. This insight informs the interpretation of studies using less-well-characterized NNMT inhibitors without the 5-amino substitution, and it supports the specific selection of 5-Amino-1MQ (rather than other quinolinium compounds) for NNMT-focused research. ^[4]

Study 3: Kraus et al., NNMT Knockdown and NAD+ Metabolism in Adipocytes (2014)

While not a direct 5-Amino-1MQ study, the Kraus laboratory's work on NNMT in adipocytes established the biological rationale that subsequent inhibitor studies have built upon. Using siRNA-mediated NNMT knockdown in 3T3-L1 preadipocytes and primary mouse adipocytes, Kraus and colleagues demonstrated that reducing NNMT expression raised cellular NAD+ levels, increased SIRT1 deacetylase activity, and suppressed the full transcriptional program of adipogenic differentiation. ^[8]

Critically, the study quantified the contribution of NNMT to the NAD+ / nicotinamide balance. In cells with high NNMT activity, a substantial fraction of available nicotinamide was diverted to MeNAM, reducing the substrate available for NAMPT-mediated NMN synthesis. This "methyl drain" mechanism is now considered the primary route by which NNMT limits NAD+ availability in adipose tissue, and it is the mechanistic backbone for extrapolating genetic knockdown findings to pharmacological inhibition with 5-Amino-1MQ.

The study's design strength lies in its use of both knockdown and overexpression systems (adenoviral NNMT overexpression as a gain-of-function control), which established bidirectionality of the metabolic effects. The limitation, as with most cell-culture adipocyte work, is the question of how well 3T3-L1 cells recapitulate primary human adipocyte biology, particularly in the context of epigenetic regulation. ^[6]

Study 4: Ruf et al., X-Ray Crystallography of NNMT-Inhibitor Complexes (2006)

Ruf and colleagues resolved the X-ray crystal structure of human NNMT bound to various substrate-mimetic inhibitors, including early quinolinium analogs. This work is the structural foundation for understanding how 5-Amino-1MQ interacts with the NNMT active site. The structure revealed a bi-lobed active site with a SAM-binding domain and a nicotinamide-binding domain, with the catalytic mechanism proceeding via direct methyl transfer in an SN2-like reaction. ^[2]

The nicotinamide-binding pocket is relatively shallow and solvent-exposed, which initially made it seem like a difficult target for tight-binding small molecules. However, the Ruf structure showed that the positive charge of the nicotinamide pyridinium ring makes an important interaction with a negatively charged residue (Asp197 in human NNMT) in the active site. The quinolinium scaffold of 5-Amino-1MQ recapitulates this electrostatic interaction, which is why it binds competitively with nicotinamide. The 5-amino group makes additional H-bond contacts that improve residence time in the pocket.

This structural knowledge is practically useful for researchers doing protein-ligand docking or trying to understand species differences in NNMT inhibition. Human and murine NNMT share approximately 91% sequence identity at the protein level, with the active-site residues being fully conserved, which supports direct translation of rodent pharmacological findings to human NNMT inhibition assays. ^[2]

Study 5: Campagna et al., NNMT in Adipose Tissue of Obese Human Subjects

Campagna and colleagues conducted a cross-sectional clinical study examining NNMT gene and protein expression in visceral and subcutaneous adipose tissue biopsies from lean versus obese human subjects undergoing elective surgery. Obese subjects (BMI greater than 35 kg/m2) had significantly higher NNMT mRNA and protein levels in visceral adipose tissue compared to lean controls (BMI less than 25 kg/m2), with a correlation between NNMT expression and both BMI and fasting insulin levels. ^[10]

This human data is important because it validates the translational relevance of the rodent NNMT inhibitor work. If NNMT is simply an artifact of rodent obesity models, the research rationale for inhibitors would be limited. The finding that human visceral adipose tissue shows the same NNMT upregulation pattern seen in murine DIO models substantially strengthens the case for pursuing NNMT inhibition as a research strategy for human metabolic disease.

The study's limitations include its cross-sectional design (no causal direction can be established), the relatively small sample sizes (N of approximately 20-30 per group in most analyses), and the reliance on bulk tissue mRNA rather than single-cell RNA sequencing, which would identify which specific cell populations within adipose tissue drive the elevated expression. Despite these limitations, this study is frequently cited as the human anchor point for the mechanistic rodent literature. ^[10]

Study 6: Eckert et al., NNMT and Skeletal Muscle Metabolism

Eckert and colleagues examined NNMT expression and activity in skeletal muscle tissue from both lean and insulin-resistant subjects and from mouse models of diet-induced insulin resistance. Unlike adipose tissue, skeletal muscle shows relatively low NNMT expression at baseline, but insulin resistance is associated with modest but measurable NNMT upregulation in the muscle of both human subjects and HFD-fed mice. ^[12]

In this context, NNMT inhibition with 5-Amino-1MQ (at literature-reported in vivo research doses) produced improvements in insulin-stimulated glucose uptake in soleus and EDL muscle strips from treated mice, measured by 2-deoxyglucose uptake assay. The effect was associated with elevated NAD+, increased SIRT1 activity, and deacetylation of IRS-1, a modification that improves insulin signaling by reducing the serine phosphorylation that normally blunts the insulin response in insulin-resistant states.

The study adds a skeletal muscle dimension to the metabolic research portfolio of 5-Amino-1MQ that complements the predominantly adipose-focused earlier literature. However, effect sizes in muscle were smaller than in adipose tissue, consistent with the lower baseline NNMT expression in this tissue. Researchers targeting specifically skeletal muscle insulin resistance may find the adipose-directed effects of NNMT inhibition to be a confounder rather than an asset if they need tissue-specific experimental designs. ^[12]

Pharmacokinetics

The pharmacokinetic profile of 5-Amino-1MQ has not been formally published in full detail in peer-reviewed literature as of this writing. The values in the table above are derived from plasma concentration data reported in the context of efficacy studies, from physical-chemical property calculations, and from the limited in vitro permeability characterizations available. This is a recognized gap in the published literature. ^[3]

The oral route is the most practically relevant for in vivo rodent research and is supported by the compound's moderate aqueous solubility and the oral tablet format offered by Apollo Peptide Sciences. Absorption from the gastrointestinal tract is facilitated by the compound's relatively small molecular size and its moderate lipophilicity. The permanent positive charge from the quaternary nitrogen is a double-edged pharmacokinetic factor: it may reduce passive membrane permeability at some barriers (particularly the blood-brain barrier), but it also reduces non-specific binding to lipophilic proteins and tissues, potentially improving the selectivity of observed pharmacological effects to NNMT-expressing tissues.

Metabolism is likely primarily hepatic, with N-demethylation or ring oxidation as probable phase I pathways, though no formal metabolite identification studies have been published for this specific compound. Researchers using 5-Amino-1MQ in hepatocyte models or in vivo liver studies should consider that the liver is both a site of NNMT action and a primary metabolizing organ, which may create concentration-dependent differences between hepatic and systemic pharmacology. ^[5]

For researchers designing in vitro experiments, the recommended approach is to run parallel NNMT activity assays in cell lysates alongside the cellular phenotype assays to confirm target engagement at the concentrations being used. A concentration that produces the maximum target engagement without cytotoxicity (confirmed by LDH or MTT assay) defines the working window for any given cell line.

Purity and Verification

What to Expect on a Certificate of Analysis

Any research-grade 5-Amino-1MQ product should be accompanied by a batch-specific Certificate of Analysis (CoA). For a 50 mg / 25-tablet product, the CoA should include identity confirmation by mass spectrometry (ESI-MS or LCMS), purity assessment by HPLC (typically reversed-phase C18), residual solvent analysis, and a moisture/water content measurement if the product is lyophilized or tablet-based.

For 5-Amino-1MQ specifically, researchers should confirm that the CoA specifies which form of the compound was analyzed (free base vs. HCl salt) and that the molecular weight used in the purity calculation matches the form being supplied. A common error in the research peptide and small-molecule market is CoAs that report purity relative to an incorrect molecular weight standard, which can overstate or understate the actual compound content per tablet. ^[13]

The HPLC trace should show a single dominant peak with no significant secondary peaks that would indicate degradation products or synthetic impurities. An acceptable purity specification for a research-grade small molecule of this type is 98% or higher by area normalization. Pay attention to the UV detection wavelength: for quinolinium compounds, detection at 254 nm and/or 320 nm is appropriate; a CoA reporting only 220 nm detection may miss impurities that absorb differentially.

Independent Verification Approach

For high-stakes research applications, do not rely solely on the supplier's CoA. An independent verification strategy typically involves three steps. First, obtain an aliquot for third-party HPLC-MS analysis through a contract analytical laboratory. Services such as those offered by academic core facilities or commercial analytical labs can confirm identity by accurate mass and assess purity within 5-10 business days at costs typically in the range of $150-$300 per sample.

Second, run a cell-based target engagement assay as a functional purity check. For 5-Amino-1MQ, a simple NNMT activity assay in a cell-free system (recombinant NNMT with radiolabeled or fluorescent substrate) will confirm that the material inhibits NNMT at the expected IC50. If the IC50 observed with the supplied material is significantly higher than the published value, this indicates either an impure product or incorrect concentration in the formulation.

Third, assess stability under your specific storage conditions. Tablet excipients can interact with the active compound under certain humidity or temperature conditions. A stability-indicating HPLC method run at the start and end of a research project provides a bracketed record of compound quality throughout the study. See our CoA reading guide for detailed protocols on interpreting these documents. ^[13]

Dosage and Reconstitution

Literature-Reported Research Doses (Animal Models)

In the primary Hong et al. rodent studies, dietary admixture and gavage protocols used dose ranges that, when expressed as mg/kg body weight in C57BL/6 mice (average 30 g body weight, 25-35 g range in DIO models), produced plasma concentrations estimated to be in the range needed for NNMT inhibition based on in vitro IC50 data. ^[3] Literature-reported research doses in rodent studies typically fall in the range of 20-100 mg/kg/day depending on the route, the specific endpoint being measured, and the duration of the study. These are animal-equivalent values and cannot be directly translated to human doses by simple body weight scaling.

For in vitro cell culture work, literature-reported research concentrations for 5-Amino-1MQ in cell-based NNMT inhibition assays range from 1 micromolar to 100 micromolar, with most functional assays using 10-50 micromolar as the primary working concentration. At concentrations above 100 micromolar in some cell types, cytotoxicity signals begin to appear, typically assessed by LDH release or Annexin V staining. Researchers should establish their own cell-type-specific toxicity threshold before beginning dose-response studies. ^[8]

Reconstitution Protocols for In Vitro Use

For cell-culture experiments, 5-Amino-1MQ tablets should first be dissolved to prepare a stock solution. A practical protocol begins with crushing one or more tablets in a clean glass mortar, then transferring the powder to a volumetric flask. The powder can be dissolved in sterile DMSO to prepare a high-concentration stock (typically 50-100 mM, given the compound's good DMSO solubility). This stock is then further diluted in cell culture medium immediately before use.

DMSO final concentration in cell culture should not exceed 0.1% (v/v) to avoid vehicle-induced cytotoxicity or off-target effects on cell signaling. For a 50 micromolar final concentration in culture medium (with 0.1% DMSO limit), this means the DMSO stock concentration should be at least 50 mM. At a molecular weight of 214.67 g/mol (HCl salt), 50 mM stock in DMSO requires dissolving 21.47 mg per 2 mL DMSO. Serial dilutions from this stock enable the construction of full concentration-response curves.

For researchers who prefer an aqueous stock, 5-Amino-1MQ has workable water solubility at approximately 10 mg/mL (approximately 46 mM free base equivalent). Aqueous stocks should be prepared in sterile phosphate-buffered saline or cell-culture-grade water and filter-sterilized through a 0.22 micron syringe filter before addition to culture.

For worked reconstitution examples and step-by-step protocols for small-molecule research compounds, see our reconstitution guide. For guidance on calculating molar concentrations, mg-to-molar conversions, and dose-volume calculations, see our dosage calculation guide.

Worked Numerical Examples

Example 1: Preparing a 10 mM DMSO stock from tablets

Tablet strength: 50 mg per tablet, HCl salt form, MW 214.67 g/mol.

Target stock: 10 mM in DMSO, volume 1 mL.

Mass needed: 10 mmol/L x 1 L/1000 x 214.67 g/mol = 0.002147 g = 2.147 mg.

One 50 mg tablet contains enough compound to prepare approximately 23 mL of 10 mM DMSO stock. Weigh out 2.15 mg of crushed tablet powder on a calibrated analytical balance, transfer to a 1.5 mL microcentrifuge tube, add 1.0 mL anhydrous DMSO, vortex for 60 seconds, sonicate in water bath for 5 minutes at room temperature to ensure complete dissolution. Store in capped amber vials at minus 20 degrees Celsius.

Example 2: Working concentration from DMSO stock in 96-well plate

From the 10 mM DMSO stock prepared above, to achieve a 25 micromolar final concentration in 200 microliters of culture medium per well:

Volume of stock needed: C1 x V1 = C2 x V2, therefore V1 = (25 x 10-6 mol/L x 0.0002 L) / (0.01 mol/L) = 0.0005 mL = 0.5 microliters per well.

0.5 microliters into 200 microliters gives a DMSO final concentration of 0.25%, which is above the safe limit. To stay within 0.1% DMSO, a 1 mM intermediate stock should be prepared: dilute 10 mM stock 1:10 in DMSO to give 1 mM. Then add 5 microliters of 1 mM intermediate stock into 195 microliters of medium for a final volume of 200 microliters and a final DMSO of 2.5% -- still too high. The correct approach: dilute further by adding 10 microliters of 1 mM stock to 390 microliters of medium, giving a final concentration of 25 micromolar in 400 microliters total with 2.5% DMSO. Instead, create a 250 micromolar aqueous pre-dilution: take 2.5 microliters of 10 mM stock and add to 97.5 microliters of serum-free medium (giving 250 micromolar), then add 20 microliters of this to 180 microliters of complete medium (10-fold dilution gives 25 micromolar final, with final DMSO of 0.025%). This serial dilution approach is standard practice for maintaining low DMSO in aqueous assays.

Example 3: Dietary admixture for rodent feeding study

Rodent (C57BL/6 mouse, 30 g body weight, target literature-reported research dose 40 mg/kg/day, assuming 4 g food intake per day):

Dose needed per gram of food: (40 mg/kg x 0.03 kg) / 4 g food = 1.2 mg / 4 g = 0.3 mg per gram of diet.

To prepare 100 grams of medicated chow: 0.3 mg/g x 100 g = 30 mg of 5-Amino-1MQ per 100 g chow.

With 50 mg tablets, dissolve approximately 0.6 tablets (30 mg) in a minimal volume of ethanol (which evaporates), mix into 100 g of powdered rodent chow, allow solvent to evaporate fully in a fume hood before presenting to animals. This approach is consistent with published dietary admixture methods for small-molecule research compounds.

Side Effects and Safety

Preclinical Tolerability Data

In the rodent studies conducted to date, 5-Amino-1MQ at literature-reported research doses has not produced overt toxicity signals in terms of body weight loss (beyond the intended fat mass reduction), food intake suppression, behavioral changes, or gross organ pathology on necropsy. Hepatic function markers (ALT, AST) measured in some DIO mouse studies remained within normal ranges at the reported research doses, which is notable given the compound's likely hepatic metabolism. ^[3]

No formal GLP toxicology studies (such as 28-day or 90-day repeat-dose toxicology in rodents following ICH S7A guidelines) have been published for 5-Amino-1MQ. This is a significant data gap for any researcher needing to justify safety margins in a new animal study protocol. Researchers should perform their own dose-range finding (DRF) studies with appropriate survival and clinical observation endpoints before committing to long-duration protocols with this compound. ^[14]

In cell culture, cytotoxicity has been observed at concentrations above approximately 100-200 micromolar in some cell lines, as mentioned above. The therapeutic index (ratio of cytotoxic concentration to effective concentration) in commonly used research cell lines appears to be greater than 10-fold based on published data, which provides a reasonable research window, but this should be verified empirically for any new cell type. ^[8]

Potential Mechanisms of Concern

Because NNMT plays a role in methylation homeostasis through SAM consumption, inhibiting NNMT raises the SAM pool. Elevated SAM availability theoretically increases the capacity for all SAM-dependent methyltransferases, including those involved in DNA methylation. Broad changes in DNA methylation patterns could have unpredictable effects in proliferating cells. This theoretical concern is the basis for caution in using NNMT inhibitors in cancer biology research without careful controls, and it is one reason why NNMT inhibition's role in cancer is complex (elevated SAM could suppress some cancers through methylation but potentially enhance others). ^[9]

Interaction with COMT (at higher concentrations) means that researchers working in catecholamine-sensitive systems should be cautious about interpreting results from experiments using 5-Amino-1MQ at concentrations significantly above its IC50 for NNMT, as partial COMT inhibition could contribute to observed phenotypes. ^[4]

Storage Safety

From a laboratory safety perspective, 5-Amino-1MQ tablets should be stored in sealed containers away from heat, moisture, and direct light. The compound is not classified as a controlled substance in the United States, European Union, or most jurisdictions as of this writing, but researchers should verify current regulatory status in their specific jurisdiction before ordering. Material Safety Data Sheet (MSDS/SDS) information should be obtained from the supplier and reviewed by the research team's safety officer before use.

How It Compares

The comparison table above contextualizes 5-Amino-1MQ within its peer research compound category. The most practically relevant comparisons for a researcher choosing between NAD+-related compounds are with NR and NMN, which raise NAD+ through precursor supplementation rather than NNMT inhibition. The mechanistic distinction matters: NR and NMN bypass the NNMT step entirely and raise NAD+ regardless of NNMT activity level, whereas 5-Amino-1MQ's effect on NAD+ is contingent on baseline NNMT activity in the target tissue. In tissues with low NNMT expression, 5-Amino-1MQ would be expected to have a smaller effect on NAD+ than in adipose tissue.

For researchers specifically interested in NNMT biology (and its contributions to the SAM pool, methylation landscape, and polyamine metabolism) rather than just NAD+ elevation, 5-Amino-1MQ is uniquely useful because it is the only commercially available, cell-permeable small-molecule NNMT inhibitor with published in vivo efficacy data. NR and NMN do not inhibit NNMT and do not affect the methyl cycle via this mechanism. ^[7]

Compared to genetic approaches (NNMT siRNA or CRISPR knockout), 5-Amino-1MQ has the advantages of fast washout kinetics, dose-dependence, and applicability to in vivo rodent models where viral delivery of CRISPR reagents to adipose tissue is technically challenging. The disadvantage is the inherent incompleteness of pharmacological inhibition versus genetic ablation, and the possibility of off-target effects. Using both approaches in parallel is the methodologically strongest design.

FK866, included in the table, is worth understanding as a conceptual negative control: it inhibits NAMPT, the enzyme that converts nicotinamide to NMN, which reduces NAD+ (opposite to 5-Amino-1MQ). In some experimental designs, the combination of FK866 (NAD+ reduction) and 5-Amino-1MQ (NNMT inhibition, NAD+ increase) can be used to probe the specific contribution of NNMT-derived NAD+ to an observed phenotype. ^[15]

Open Research Questions

The published literature on 5-Amino-1MQ is coherent but limited in scope. Several important questions remain unresolved and represent active research frontiers.

Human pharmacokinetics. No published human PK data exists for 5-Amino-1MQ. The compound's oral bioavailability, Cmax at relevant doses, metabolic half-life, and metabolite profile in humans are entirely unknown from published sources. This is the single largest translational gap.

Long-term safety in chronic dosing models. Published rodent studies have used durations of 2-6 weeks. Whether chronic NNMT inhibition over months or years produces compensatory upregulation of NNMT, adaptive changes in the NAD+/methyl cycle balance, or tissue-specific toxicity is not established. ^[14]

Epigenetic consequences. Raising the SAM pool by diverting nicotinamide away from MeNAM synthesis should in principle increase the capacity for methylation across the epigenome. Whether this produces beneficial effects (restoring age-associated loss of DNA methylation patterns), adverse effects (hypermethylation of tumor suppressor loci), or negligible net change in whole-tissue methylation arrays has not been systematically characterized for 5-Amino-1MQ specifically. ^[9]

Cognitive and neurological effects. Despite low brain NNMT expression in healthy tissue, some NNMT activity exists in astrocytes and is relevant to neurotoxin metabolism. Whether NNMT inhibition in brain tissue has pro-cognitive effects (via NAD+ elevation) or potential risks (via altered catecholamine metabolism through partial COMT inhibition at higher concentrations) is an open question. ^[11]

Combination with NAD+ precursors. A potentially interesting research question is whether combining 5-Amino-1MQ (blocking the nicotinamide drain) with NR or NMN (adding NAD+ precursor flux) produces synergistic NAD+ elevation or whether the effects plateau. No published combination studies exist. ^[7]

Where to Buy

Apollo Peptide Sciences offers the 5-Amino-1MQ 50 mg / 25-tablet product reviewed here. For full details on this specific product, including any current batch CoA and supplier quality documentation, see the 5-Amino-1MQ 50mg product page on this site.

Researchers evaluating suppliers for any research compound should apply consistent quality criteria regardless of price. Key factors include: independent third-party HPLC and MS verification per batch, transparent disclosure of salt form and counterion, lot-specific rather than generic CoAs, clear statements of intended use (research only), and responsive technical support for researchers with analytical questions. Our supplier evaluation guide provides a structured framework for applying these criteria across the research compound marketplace.

For context on how this product fits within the broader 5-Amino-1MQ market, pricing at $75.00 for 1,250 mg total (50 mg per tablet x 25 tablets) equates to approximately $0.060 per milligram. Competing suppliers offering powder formats typically price this compound in the range of $0.04-$0.10 per milligram depending on batch size and purity tier. The tablet format offers convenience for rodent feeding studies but may carry a modest premium over loose powder.

Researchers who need very large quantities for multi-arm rodent studies may find bulk powder formats more economical. Researchers who need small, pre-measured quantities for pilot cell-culture work or who lack accurate small-mass weighing capability in their laboratory may find the 50 mg per tablet format practically advantageous. See our guide to selecting research peptide suppliers for a full comparison framework.

FAQ